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Search strategy and selection criteria 
For this Review, each contributing author selected references that s/he viewed as most 
relevant for their particular topic. The authors used systematic reviews and meta-analyses, 
where available, and also, expert reviews, classical articles, and recent articles that 
demonstrate cutting edge advances in the field. Dr Khandaker electronically searched the 
Medline-PubMed database from its inception until 22 September 2014 for studies of anti-
inflammatory agents in schizophrenia and related psychosis. Search terms included Mesh 
terms: ("Schizophrenia"[Mesh] OR "Psychotic Disorders"[Mesh]) AND ("Anti-Inflammatory 
Agents, Non-Steroidal"[Mesh] OR "Anti-Inflammatory Agents"[Mesh] OR 
"Minocycline"[Mesh]). Selected studies were published in the English language, included 
cases of schizophrenia and related psychotic disorders, and were observational, clinical trial, 
case series or case report by design. Studies that did not report primary data, such as reviews 
or trial protocols were excluded. Studies of anti-inflammatory agents in disorders other than 
psychosis were also excluded. Electronic search identified 157 studies, of which 19 were 
selected after screening of title, abstract, and examination of full article content (see Table 1). 
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Summary 
Complex interactions between the immune system and the brain may have important 
aetiological and therapeutic implications for neuropsychiatric brain disorders. A possible 
association between schizophrenia and the immune system was postulated over a century 
ago, and is supported by epidemiological and genetic studies pointing to links with infection 
and inflammation. Contrary to the traditional view that the brain is an immunologically 
privileged site shielded behind the blood-brain-barrier, recent studies have demonstrated 
complex interactions between the immune system, systemic inflammation and the brain that 
can lead to changes in mood, cognition, and behaviour. Here, we review some of the 
important areas of research regarding innate and adaptive immune response in schizophrenia 
and related psychotic disorders that, we think, will be of interest to psychiatric clinicians and 
researchers. We discuss potential mechanisms and therapeutic implications of these findings 
including studies of anti-inflammatory agents in schizophrenia, highlight areas for 
development, and offer testable hypothesis for future investigations. 
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Introduction 
Complex immune-brain interactions that affect neural development, survival, and function 
may have aetiological and therapeutic implications for a number of disorders of the central 
nervous system (CNS),
1-5
 including psychiatric illness.
2
 Multiple sclerosis, previously 
considered to be solely neurological, is increasingly recognised as secondary to immune 
dysfunctions.
3
 Higher levels of the circulating proinflammatory cytokine interleukin (IL) 6 in 
childhood have been reported to be associated with increased risks of subsequent psychosis 
and depression in young adult life;
2
 while elimination of auto-antibodies against neuronal cell 
surface proteins by immunotherapy has led to symptomatic improvement in some cases of 
first episode psychosis.
6
 This review considers whether we are entering a new era of 
immuno-psychiatry that will change our understanding of the brain’s maladies where 
manifestations include, but are rarely restricted to, mental symptoms. Accumulating 
evidence, of considerable breadth and depth, supports a role for immune system in the 
pathogenesis of depression and schizophrenia, which is consistent with the well-known 
clinical and aetiological (including genetic) overlap between these disorders.  In this review, 
we highlight some of the important areas of research implicating the innate and adaptive 
immune response in the pathogenesis of schizophrenia and related psychotic disorders 
through effects on neurotransmitters, neurodevelopment, and degeneration. We discuss 
potential therapeutic implications of these findings as well as existing treatment studies of 
anti-inflammatory agents in schizophrenia.  
 
The aim of this review is not only to summarise key evidence regarding the link between 
immune system and schizophrenia but also to identify gaps in knowledge, and to provide 
suggestions for improvement including testable hypothesis for future investigations. The aim 
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is also to give a holistic view, rather than an exhaustive review, of a landscape that may be of 
increasing relevance to people with schizophrenia and those who treat them. 
 
The immune system and the brain share some fundamental characteristics. Both are highly 
integrated, complex systems with memory that develop through interactions with the external 
environment, able to distinguish between self and non-self, and respond adaptively.
7, 8
  
Historically, the brain has been considered as an immunologically privileged site shielded 
behind the blood-brain-barrier (BBB),
9
 but immune components of the brain, such as 
microglia that constitute about 10% of the brain cell mass (equal to neurons), derive from the 
haematopoietic system beyond the CNS.
10
 In response to systemic inflammation, microglia 
release cytokines which bind to specific receptors on neurons,
8
 and affect neurotransmitters, 
synaptic plasticity, and cortisol levels, leading to changes in mood, cognition, and 
behaviour.
1, 5
 
 
In the following section, we briefly summarise epidemiological and genetic studies that 
suggest a link between inflammation, immunity, and psychosis. Next, we review specific 
abnormalities of the immune system seen in schizophrenia and related psychosis. Finally, we 
discuss the potential role of these changes in pathogenesis and treatment of psychotic illness 
including existing studies of anti-inflammatory agents in schizophrenia. 
 
The immune and infection link to psychosis 
The immune system consists of a complex organisation of cells and mediators which has 
evolved largely to protect us from infection and malignancy.
8
 It can be broadly 
conceptualised as consisting of an innate response, acting as a rapid, non-specific, first line of 
defence, and an adaptive response that is slower and antigen specific. The innate response is 
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mediated by neutrophils and macrophages that recognize and clear invading organisms. 
Inflammatory cytokines, secreted by macrophages and other cells, aid this process. The 
adaptive response involves immunological memory, and consists of T (thymic) lymphocytes 
that recognize antigen and cause lysis of infected cells, and B lymphocytes that secrete 
antibodies as part of the humoral response.
8
 
 
Schizophrenia is a disabling disorder characterised by positive (delusions and hallucinations), 
negative (social withdrawal and apathy), and cognitive symptoms (poor executive function 
and memory). It affects around 1% of the population at some point in their life, with onset 
characteristically during the epoch of brain development that follows puberty and lasts until 
the end of the third decade.
11
 Schizophrenia is multifactorial: it is associated with multiple 
genetic loci conferring risk as well as with developmental and postnatal risk factors.
12
 A 
possible association between schizophrenia and the immune system was postulated more than 
a century ago (Box 1), and is supported by epidemiological studies pointing to links with 
infection and systemic inflammation.
13-16
  
 
 
 
 
 
 
 
 
 
Text box 1: The link between immune system and psychosis has a long history  
 
 1870, Alexander Rosenbilum published a case series of psychotic states in 
febrile episodes of malarial infection. 
 1910, Julius Wagner-Jauregg was awarded the Nobel Prize for medical 
inoculation of malarial parasites as a treatment for syphilitic psychosis.  
 1926, Karl Menninger published a case series of post-influenzal psychosis 
in the American Journal of Psychiatry. 
 1929, Moritz Tramer reported an association between schizophrenia and 
winter or spring birth. 
 1937, Lehman Facius described auto antibodies against brain structures in 
CSF of patients with schizophrenia. 
 1988, Sarnoff Mednick and colleagues reported increased risk of 
schizophrenia in adult offspring of women pregnant during the 1957 
influenza pandemic. Although subsequent meta-analysis of ecological 
studies did not find an association between pandemic influenza and 
schizophrenia, these findings spurred a great deal of research leading to 
some important discoveries regarding early-life infection and 
schizophrenia using serological data of prenatal maternal infection (see 
below). 
 1992, Ronald Smith proposed a macrophage-T-lymphocyte theory of 
schizophrenia. 
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Serologically confirmed prenatal maternal infection with any of several pathogens, including 
influenza, herpes simplex virus type 2, cytomegalovirus, and the intracellular parasite 
Toxoplasma gondii, clinically diagnosed non-specific viral and bacterial infections, elevated 
maternal CRP levels during pregnancy, all have been associated with schizophrenia in the 
adult offspring.
15, 17
 Lower levels of acute phase proteins in neonates might increase the risk 
of adult psychosis by increasing susceptibility to infections in the early-life.
18
 Acute phase 
proteins are released as part of the innate immune response, and consist of several mediators 
with different physiological functions.
8
 Exposure to neurotropic virus in early childhood is 
associated with increased risk of sub-clinical psychotic experiences in adolescence.
19
  The 
finding that the risk of schizophrenia is almost doubled in adult survivors of childhood CNS 
viral infection demonstrates that the period during which infection may increase the risk of 
future neuropsychiatric disorders is not confined to prenatal period.
14
 Adult schizophrenia is 
also associated with increased rates of various infections, including those caused by 
Toxoplasma gondii.
20
 
 
Childhood auto-immune conditions are associated with sub-clinical psychotic experiences in 
adolescents
21
 and schizophrenia in adults.
22
  The prevalence of auto-immune conditions is 
increased in people with schizophrenia and their unaffected first degree relatives.
23
 Besides, 
risk of schizophrenia increases in a linear fashion with the number of severe infections in 
individuals with a previous history of auto-immune disease.
22
 Thus, the links between 
schizophrenia and a range of infections and autoimmune conditions suggest a common 
underlying pathway, most likely involving the inflammatory immune response. In addition to 
its own effects on the brain, inflammation is thought to increase the permeability of the BBB 
and to facilitate penetration of immune components into the brain.
24
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Support for an immune-mediated aetiology in schizophrenia comes from genome wide 
association studies (GWAS), reporting significant associations between schizophrenia and 
markers close to the major histocompatibility complex (MHC) region on chromosome six.
25, 
26
 This region contains many immune-related genes, including those involved in antigen 
presentation and inflammatory mediators.  A recent GWAS has identified 108 genetic loci 
(83 previously undetected) associated with schizophrenia: broadly, these represent genes 
expressed in the brain, and immune cells involved in adaptive immunity (CD19 and CD 20 
B-lymphocytes) as well as the MHC.
27
 Moreover, associations for the immune related genes 
remained significant after the MHC region was excluded suggesting these findings were not 
driven by the strong association at the MHC. Another GWAS found significant genetic 
overlap involving the MHC region between schizophrenia and multiple sclerosis, a condition 
characterised by immune dysfunction.
28
 
 
The immune system in the pathogenesis of schizophrenia and related psychosis 
The abnormalities of the immune system seen in schizophrenia and related psychosis are 
diverse and overlapping, involving a number of immune components. Here, we first consider 
the components of the innate immune response, including cytokines and microglia; second, 
we describe components of the adaptive immune response, including lymphocyte subsets and 
anti-neuronal cell surface antibodies. We do not cover autoimmunity involving various brain 
regions, thyroid, thymus, and antibodies to dietary antigens such as gliadin and casein. Key 
questions pertaining to the entire field have been summarised in box 2.  
 
Heterogeneity between studies may point towards uncertainty or may reflect heterogeneity in 
the causes and pathogenesis of the schizophrenia syndrome. Changing the focus of research 
from syndrome to symptom or constellation of symptoms would be helpful to fully 
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understand the role of inflammation and immunity in neuropsychiatric disorders. Many 
current studies have inadequately accounted for confounding factors such as body mass and 
smoking. More have focused on blood rather than CNS immune markers while few have 
examined relationships between immune markers and either symptoms or cognition in 
schizophrenia. Rarer still are longitudinal studies of immune markers and schizophrenia that 
comment on cause and effect between immunity and psychiatric syndrome. Relationships 
between immune markers, stress, and cortisol in schizophrenia are also poorly understood. 
We have highlighted these issues along with suggestions for development in relevant 
sections. Despite these lacunae in the literature, current knowledge is consistent with a role 
for the immune system in the pathophysiology of schizophrenia and related psychotic 
disorders. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Text box 2: A few key research questions regarding immunological aspects of 
schizophrenia, related psychosis and other mental illness 
 
1. Is elevated serum concentration of proinflammatory cytokines a cause or 
consequence of schizophrenia? 
2. Could systemic inflammatory markers be used to identify prodromal 
cases of schizophrenia, to predict disease progression, response to 
antipsychotic treatment and recovery? 
3. Could inflammatory processes explain cognitive deficits, progressive 
cognitive decline and brain volume loss in some cases of schizophrenia? 
4. Could inflammatory processes explain the association between early-life 
adversity and risk of psychiatric disorders in adult life? 
5. Does activation of microglia correspond with clinical severity of 
schizophrenia and response to antipsychotic treatment? 
6. What is the role of neuronal cell surface auto-antibodies in schizophrenia 
and other psychiatric disorders? 
7. What is the prevalence of neuronal cell surface antibodies in 
schizophrenia, other psychiatric disorders and healthy controls?  
8. Does the prevalence of neuronal cell surface antibodies depend on the 
phase of the illness? Are there clinical signs that predict a positive test? 
9. Are there other peripheral biomarkers associated with neuronal cell 
surface antibodies which could form therapeutic targets? 
10. What is the relationship between intestinal microbiota and inflammatory, 
behavioural, cognitive and neurochemical phenotypes seen in 
schizophrenia and other psychiatric disorders? 
11. What is the response of antibody associated psychosis to 
immunosuppression or antipsychotic treatment? 
12. Does controlling inflammation lead to clinical improvement in psychosis 
and other mental illness? 
13. Is stratification of patients based on their immune phenotype helpful with 
regards to predicting response to conventional and/or novel treatments?  
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Inflammatory cytokines 
Meta-analyses of many cross-sectional studies show that schizophrenia is associated with 
disruption of the cytokine milieu and the propensity for the production of proinflammatory 
cytokines.
16, 29, 30
 Longitudinal studies of inflammatory markers and subsequent psychotic 
disorders are scarce. Recent findings from the ALSPAC birth cohort suggest that higher 
serum levels of the proinflammatory cytokine IL-6 at age 9 years confers a two-fold risk of 
developing psychotic disorder at age 18 years.
2
 The study also reports a robust, dose-response 
relationship between higher IL-6 levels in childhood and subsequent risk of sub-clinical 
psychotic experiences in young adulthood, which persists after taking into account a number 
of potential confounders including gender, body mass, and psychological and behavioural 
problems preceding the measurement of childhood IL-6.
2
 No associations between serum 
CRP levels at baseline and future psychiatric disorders were observed, but another 
longitudinal study reported increased risk of late or very late onset schizophrenia for higher 
serum CRP levels at baseline.
31
 Further longitudinal studies are needed to confirm whether 
the increase in serum levels of proinflammatory cytokines in schizophrenia and related 
psychosis is the cause or consequence of illness, though these findings suggest they point 
towards causal mechanisms. 
 
Antipsychotic naïve first episode psychosis
30
 and acute psychotic relapse
16
  are also 
associated with increased serum levels of IL-6 and other proinflammatory cytokines, such as 
tumour necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), and decreased serum levels 
of anti-inflammatory cytokine IL-10, which are normalised after remission of symptoms with 
antipsychotic treatment.
16
 Reduced IL-2 production in vitro by T cells collected from 
schizophrenia patients has been reported,
32
 but acute psychosis is associated with no 
significant changes in serum IL-2 levels.
16
 There is an increase in levels of soluble IL-2 
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receptor (sIL-2R),
16, 30
 which is likely to be a compensatory mechanism inhibiting IL-2 
production. Thus, the data are consistent with an increase in proinflammatory cytokines in 
acute psychosis. However, a few studies have adjusted for important immune-modulatory 
factors such as body mass or smoking,
16
 or examined cytokines in CSF where increase in IL-
6
33, 34
 has been reported in schizophrenia. One study has reported increased serum IL-6 
concentration in people with at-risk mental state for psychosis compared with healthy 
controls.
35
 Some data suggest that serum cytokine concentrations including IL-6 are 
associated with illness severity, duration, and antipsychotic therapy,
16, 36, 37
 but we know little 
regarding the associations between stress, cortisol and cytokine levels in different stages of 
schizophrenia. Therefore, more studies are required to understand the relationships between 
cytokine levels, disease prodrome, progression and treatment response. Longitudinal studies 
of first episode psychosis, individuals at clinical high risk for developing psychosis as well as 
those with treatment refractory illness would be useful to examine these issues. Rather than 
merely demonstrating group differences in cytokine serum or CSF levels, future studies 
should examine associations between cytokines, cognitive and social functioning, comorbid 
physical illness, and structural and functional brain indices in people with psychosis and 
healthy controls.  
 
In rodents studies have demonstrated physiological roles of cytokines in memory and 
learning, including long-term potentiation, synaptic plasticity and neurogenesis (for review 
see).
38
 Recently, mild systemic inflammation has been reported to produce impairments in 
spatial memory in humans via its action on glucose metabolism in the medial temporal lobe.
39
 
Whether cytokine-mediated inflammatory processes underlie cognitive dysfunction in 
schizophrenia, an integral part of the syndrome, is an important hypothesis that requires 
investigation.  
12 
 
Longitudinal associations between IL-6 and both psychosis and depression may indicate a 
trans-diagnostic effect.
2
 A longitudinal association between serum C-reactive protein, a 
marker of systemic inflammation, and subsequent symptoms of post-traumatic stress disorder 
has been reported.
40
 Thus, understanding the early-life bio-psycho-social determinants of 
cytokine serum concentrations would be crucial in order to elucidate whether increased levels 
of cytokines could explain the association between early-life adversity and the risk of various 
psychiatric illnesses in adulthood.
41
 
 
Studies using mouse models have demonstrated how peripheral cytokines, such as IL-6, can 
affect the brain (figure 1) (for reviews see).
1, 4
 Circulating IL-6 binds to receptors on the 
vagus nerve, and the signal reaches hypothalamic brain nuclei via brainstem by retrograde 
axonal transport. Once within the CNS, the cytokine signal is amplified, which activates 
microglia, leading to the secretion of proinflammatory cytokines, chemokines, and proteases 
within the brain.
1
 These messengers activate indoleamine 2, 3 dioxygenase, an enzyme that 
metabolizes tryptophan along the kynurenine pathway, leading to increased levels of 
kynurenic acid and its metabolite quinolonic acid, both of which are involved in 
glutamatergic neurotransmission.
42
 Cytokines also increase oxidative stress by raising the 
concentration of toxic nitric oxide, and activate the hypothalamic-pituitary-adrenal axis 
leading to the release of cortisol.
1, 5
 These effects could contribute to the negative, cognitive 
and positive symptoms of schizophrenia, as well as to impaired mood, cognition, and 
perception that are important parts of other psychiatric disorders. Indeed non-specific 
peripheral immune activation caused by injection of lipopolysaccharide in healthy volunteers 
increases serum IL-6 levels as well as inducing low mood, anxiety and reduced cognitive 
performance.
43
 Furthermore, cytokines have significant effects on microglia that, in turn, are 
crucial for the maintenance of effective neuronal and synaptic health.
10
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--- Insert Figure 1 here --- 
 
Figure 1: How peripheral immune signals reach the brain to contribute to 
neuropsychiatric symptoms  
 
 
Microglia 
Microglia, the resident immune cells of the brain, constitute 10% of all non-neuronal or glial 
cells which, in turn, constitute 90% of the adult human brain.
10
 Similar to macrophages, these 
cells originate from myeloid precursor cells and are thought to migrate into the CNS during 
the early neonatal period.
44
 Within the normal brain, microglia retain a down-regulated 
phenotype (‘resting state’),45 yet continue to survey and respond to the surrounding brain 
micro-environment (see video – http://www.nature.com/news/microglia-the-constant-
gardeners-1.10732). If the brain is subject to injury, inflammation, or in response to systemic 
inflammation, microglia develop an ‘activated’ phenotype characterised by morphological 
changes, up-regulation of surface receptors, the potential to activate T cells, and the release of 
various inflammatory mediators including cytokines.
46
  
 
Neuroinflammation is characterised by the activation of microglia cells, which show an 
increase in the expression of the peripheral benzodiazepine receptor. Neuroimaging studies 
using positron emission tomography and a peripheral benzodiazepine receptor ligand provide 
evidence for neuroinflammation in recent onset schizophrenia,
47
 and in acute exacerbations of 
schizophrenia.
48
 They indicate increased binding of this ligand in the entire grey matter and 
the hippocampus, suggesting that neuroinflammation might contribute to grey matter volume 
loss and cognitive deterioration in schizophrenia.
47, 48
 However, such studies are limited in 
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number and the existing studies have included small numbers of people with schizophrenia 
and healthy controls. An alternative explanation for increased binding of the benzodiazepine 
receptor ligand could be its affinity for activated astrocytes, which are seen in schizophrenia 
but are unrelated to neuroinflammation.
48
 Many patients with schizophrenia are treated with 
benzodiazepines, which can also influence binding of this ligand. Thus, there is a need for 
identifying reliable markers of microglial activation that can be used for in vivo imaging or 
measured in blood in order to investigate whether microglial activation corresponds with 
clinical severity and treatment response. 
 
Previously activated microglia may respond more strongly to a new stimulus.
49
 Microglia are 
likely to retain an immune memory of the neuropathology, which, in turn, is associated with 
heightened responsiveness to new systemic inflammation.
46
 Thus, early developmental 
insults such as childhood CNS or severe systemic infection may have a priming effect on 
microglia,
49
 increasing microglial activation and psychosis risk following subsequent 
infections. Whether the association between early-life CNS infection and adult 
schizophrenia
14
 could be explained by changes in microglia can be tested using longitudinal 
birth cohorts. Induced pluripotent stem cell technology has been successfully used to create 
neurons by reprogramming human fibroblast cells:  neurons derived from schizophrenia 
patients have diminished neuronal connectivity, decreased neurite number and glutamate 
receptor expression compared with neurons derived from healthy controls.
50
 It remains to be 
seen whether this technology can be utilized to study non-neuronal brain cells such as 
microglia. 
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Anti-neuronal cell surface auto-antibodies   
A possible role of brain reactive auto-antibodies in the aetiology of schizophrenia has been 
discussed since the early twentieth century.
51
 Auto-antibodies against components of various 
brain regions, cellular proteins, and dietary antigens such as gliadin and casein in serum and 
cerebrospinal fluid have been demonstrated in schizophrenia and related psychosis (for 
reviews see).
52, 53
 More recently, antibodies against neuronal cell surface targets, N-methyl-
D-aspartate receptor (NMDAR) and components of the voltage-gated potassium channel 
complex, have been reported in some patients with first episode psychosis and DSM-IV 
schizophrenia.
6, 54-57
 Some of these antibodies have been typically associated with anti-
NMDAR encephalitis, a progressive illness that often starts with psychotic symptoms and/or 
seizures, and subsequently manifests other neurological and autonomic features.
58
 When 
present in patients with encephalitis, the antibodies are considered pathogenic, and removal 
of the antibodies is associated with clinical improvement. Early identification of the 
antibodies and treatment with immunotherapy has been reported to predict good clinical 
outcome.
59
 It remains to be tested whether this is also the case for patients with antibodies 
and a purely psychiatric presentation, although there are a few case descriptions to support 
this.
6
 Randomised controlled trials (RCT) of immuno-therapy as an adjunct of standard 
antipsychotic treatment for antibody-associated cases of psychosis are required to examine 
this question. 
 
It is possible that NMDAR antibody seropositivity in some people with psychosis is in fact 
undiagnosed anti-NMDAR encephalitis. However, it has been argued that diagnostic 
misclassification is unlikely to be the sole explanation for this because almost none of the 
NMDAR antibody seropositive cases of psychosis has IgG class NMDAR antibodies against 
the NR1 subunit alone (one of the subunits of the NMDAR antibody).
57, 60
 An association 
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between NMDAR antibody and schizophrenia is biologically plausible. In healthy volunteers, 
NMDAR blockade with ketamine produced psychotic symptoms.
61
 Furthermore, a recent 
study has shown that de novo mutations, in the form of chromosomal copy number changes, 
affect glutamatergic post-synaptic proteins that form part of the NMDAR.
62
   
 
NMDAR antibody seropositivity is not limited to patients with schizophrenia alone. Patients 
with psychiatric disorders such as schizophrenia, depression, and bipolar disorder are 
collectively about three times more likely to have elevated NMDAR antibody titers compared 
with controls based on high-specificity (but not low-specificity) seropositivity thresholds.
60
 
This underscores the need for further cross-sectional and longitudinal studies of psychiatric 
cases and healthy controls employing standardized assay methods and seropositivity 
threshold definitions. Preclinical studies are also needed to elucidate pathogenic mechanisms 
of these antibodies in psychosis and other mental illness. 
 
T lymphocytes 
T cells are thymus derived lymphocytes which, very simply, can be considered as either 
‘CD8 expressing’ cytotoxic cells or ‘CD4 expressing’ helper cells, and may have both 
proinflammatory and anti-inflammatory roles. Recent evidence suggests a role for T cells in 
the aetiology of schizophrenia. Acute psychosis is associated with the activated phenotype of 
lymphocytes within the CNS compared with controls.
63
  In post mortem studies, 
immunohistology has allowed direct visualisation of increased T cell as well as B cell 
numbers within the hippocampus in patients with schizophrenia.
64
 These changes were 
particularly evident in those with predominantly negative, compared with positive 
symptoms.
65
 However, there are inconsistencies between studies as to whether schizophrenia 
is associated with increased or decreased numbers of lymphocytes in the peripheral 
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circulation. A recent meta-analysis has reported increased numbers of cells positive for CD56 
(a marker of natural killer cells and activated T cells), and a higher CD4/CD8 T cell ratio in 
schizophrenia.
66
 It also highlighted important limitations of the existing data.  Many studies 
do not control for immune-mediating variables, such as smoking, body mass, stress-
associated cortisol levels, and medication. Findings from individual studies are difficult to 
compare because they report percentages rather than cell numbers. 
 
Well-controlled studies reporting absolute cell numbers are required to fully understand any 
associations between T cells and schizophrenia. Since schizophrenia is a heterogeneous 
condition, one might speculate that different T cell subtypes are associated with differing 
symptomatology. Thus studies of T cells after stratification of cases by symptom profile may 
be more informative. In order to fully understand the role of T cells in schizophrenia, an 
understanding of the function of these cells is also required. Future studies should assess the 
cytokine profile of these cells, their activation status, and gene expression profile. 
 
How might immune dysregulation lead to the manifestation of schizophrenia? 
Effects on neurotransmitters 
Studies in animal models suggest an association between prenatal infection/ inflammation 
and disturbance of neurotransmitter systems (glutamate, dopamine and GABA) in the 
offspring,
67
 but little is known about the direct effects of the inflammatory immune response 
on neurotransmitter systems in humans. NMDAR antagonism and glutamatergic 
hypofunction have long been proposed as underlying mechanisms for psychotic symptoms 
and cognitive dysfunction in schizophrenia.
61, 68
 There is evidence that proinflammatory 
cytokines increase the concentration of kynurenic acid, which is a metabolite of tryptophan 
and the only naturally occurring NMDAR antagonist in the human CNS (figure 2).
69, 70
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--- Insert Figure 2 here --- 
 
Figure 2: Possible mechanisms of immune-mediated aetiology of psychosis 
 
 
Studies of the cyclooxygenase (COX) pathway may lead to a better understanding of the role 
of kynurenic acid in psychosis. COX-1 inhibition increases levels of kynurenic acid while 
COX-2 inhibition decreases them.
71
 This might explain some of the side effects of COX-1 
inhibitors, such as psychotic symptoms and cognitive dysfunction. On the other hand, 
Celecoxib (a selective COX-2 inhibitor) has been reported to improve clinical symptoms in 
schizophrenia.
72, 73
 Thus, systematic evaluation of the neuropsychiatric side-effects of COX-1 
and COX-2 inhibitors from existing RCT data would be useful. 
 
The relationship between neurotransmitters and immune mediators may be reciprocal with a 
few publications reporting immunoregulatory functions for dopamine; for review see.
74
 T 
cells express dopamine receptors, the stimulation of which promotes up-regulation of 
adhesion molecules and cytokine production.
75, 76
 Increased expression of the dopamine D3 
receptor and increased synthesis of the pro-inflammatory cytokine IFN-γ by lymphocytes 
have been reported in un-medicated patients with schizophrenia.
77
 The opposite has been 
observed in Parkinson’s disease,78 a condition characterised by CNS dopamine depletion. 
Further studies are required to understand the effects of inflammation on neurotransmission 
and vice versa in healthy people and those with psychiatric disorders. 
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Effects on neurodegeneration 
Progressive clinical deterioration, cognitive decline, loss of cortical grey matter along with 
histopathological evidence of neuronal atrophy and reductions in the number of neuronal 
synapse and dendrites, all suggest a neurodegenerative process is active in schizophrenia 
beyond that seen in healthy subjects.
79-81
 Activated microglia are increasingly being 
recognised as an important component in the pathogenesis of other degenerative brain 
conditions, such as Alzheimer’s disease, where they appear to have wide ranging effects.46 Is 
this also the case in schizophrenia? Microglial activation interferes with neuronal survival by 
increasing oxidative stress and decreasing neurotrophic support.
5
 Schizophrenia is associated 
with changes in serum, plasma, and red blood cell markers of oxidative stress.
82
 Recently a 
population-based longitudinal study has reported a strong association between delirium and 
subsequent dementia and cognitive decline in older adults, which is not mediated by classical 
neuropathologies associated with dementia.
83
 It is possible systemic inflammation, a common 
cause of delirium, underlies this association. Indeed severe systemic illness in the elderly has 
been reported to be associated with subsequent cognitive decline and functional 
deterioration.
84, 85
 In the future, studies should examine whether inflammatory processes 
could explain progressive cognitive decline and brain volume loss in some cases of 
schizophrenia.  
 
Effects on neurodevelopment 
Interference with brain development from early-life infection/inflammation is consistent with 
a neurodevelopmental view of schizophrenia.
86, 87
 Given the association of adult 
schizophrenia with a variety of early-life infections, (for reviews see)
14, 15
 it is likely that a 
common pathway, the proinflammatory immune response, is involved. This notion is 
supported by animal model studies. Simulated viral or bacterial infection or direct injection 
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with IL-6 in pregnant mice has been reported to produce intermediate phenotypes related to 
schizophrenia in the adult offspring.
88
 Some of these phenotypes, such as deficits in sensory 
gating and abnormal latent inhibition, are reversible by treatment with clozapine.
89
 Since 
infections are widespread in the general population, interactions with genetic or other factors 
are likely. Indeed an additive effect of family history of psychosis and prenatal infection in 
the causation of schizophrenia has been reported in a Finnish cohort.
90
 In the future studies 
should examine gene-infection interaction, and whether there is a ‘sensitive period’ during 
development when exposure to infection is more harmful. 
 
GWAS and epidemiological studies indicate some overlap of genetic susceptibility between 
schizophrenia and serious infection.
26, 91
 Childhood infection may have a priming effect on 
microglia (discussed above). Thus, it is possible that early-life infection, by affecting gene 
expression or in the presence of pre-existing genetic liability, can lead to a distinct or 
pathological immune response. This may, in turn, lead to CNS alterations making these 
individuals susceptible to developing psychotic illness later in life. Studies with detailed 
phenotypic characterisation of early development as well as immune and genetic data are 
necessary to test this hypothesis. 
 
The human microbiome and the gut-brain axis: an emerging area of interest 
The intestinal microbiota consists of a vast bacterial community that resides primarily in the 
lower gut and lives in a symbiotic relationship with the host. A bidirectional neurohumoral 
communication system, known as the gut-brain axis, integrates the host gut and brain 
activities. The intestinal microbiota is thought to influence brain development and function 
via this axis, and thus, may be relevant for neuropsychiatric disorders.
92, 93
 Bacterial 
colonization of germ-free mice increases metabolism of tryptophan leading to over two-fold 
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increase in concentrations of 5-hydroxy tryptophan and its metabolites including kynurenic 
acid (relevant for psychosis; see above). An animal study suggests that manipulation of the 
intestinal microbiota can alter host cognitive function and behaviour.
94
 
 
The vagus nerve, which plays a central role in relaying the systemic cytokine signal to the 
brain (discussed above), may be also important for gut-brain communication. In mice, 
anxiolytic and antidepressant effects of feeding a specific strain of Lactobacillus can no 
longer be seen after vagotomy.
95
 There is evidence of greater intestinal inflammation in 
individuals with schizophrenia compared with controls, and similarly, in people with first 
episode psychosis who have not taken antipsychotics compared with those receiving 
antipsychotics.
96
 Studies in animals
97
 and humans
98
 suggest that manipulation of the gut 
microbial composition influences systemic cytokine levels. Thus, it is possible that intestinal 
microbiota affect the brain and behaviour by influencing systemic cytokine levels in 
schizophrenia. This is an important hypothesis that warrants examination. In the future, 
studies should examine the relationships between intestinal microbiota and behavioural, 
cognitive and neurochemical phenotypes in psychiatric disorders and healthy controls. 
 
Therapeutic implications of an immunological and inflammatory understanding of 
schizophrenia and other mental disorders 
Current understanding of the association between the immune system and risk of psychotic 
disorders hold promise for novel approaches for detection, treatment and prevention. These 
may include developing or ‘repurposing’ drugs to target inflammatory pathways, 
immunotherapy for antibody-associated cases of psychosis and other mental illness, and 
stratification of patients by their immune phenotype in order to inform treatment decision and 
to measure treatment response. Indeed, a recent molecular study has reported two distinct 
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subgroups of schizophrenia patients characterised by predominant abnormalities in either 
immune molecules or growth factors and hormones.
99 
 
RCTs of anti-inflammatory agents as adjunct to standard therapy have shown promising 
results in schizophrenia (table 1), although such trials are few and have often involved small 
samples.
100
 Celecoxib has been reported to improve cognitive function in early stages of 
schizophrenia,
101, 102
 but the use of COX-2 inhibitors is problematic as they can increase risk 
of heart disease.
103
 Recently, Minocycline, a centrally acting tetracyclic anti-inflammatory 
agent, has been reported to improve negative symptoms and cognitive function in 
schizophrenia.
104, 105
  Large multi-centre trials are required, with stratification of patients by 
their immune phenotype.  This approach proved useful in a recent RCT of infliximab (a TNF-
α antagonist) in treatment-resistant depression, in which no overall efficacy was observed but 
it improved depressive symptoms in patients with high concentrations of inflammatory 
markers at the start of the trial.
106
 It has been suggested that lack of clinical benefit from 
conventional antidepressants may be related to activation of the inflammatory system.
107
 In 
the future, RCTs should focus on specific patient groups characterised by, for example, 
resistance to conventional antipsychotics, presence of a defined pattern of immune activation, 
such as a predominantly proinflammatory molecular signature, or symptom profile, such as 
predominant negative symptoms or cognitive dysfunction. 
 
Identification of specific inflammatory pathways for neuropsychiatric symptoms would 
provide novel targets for therapeutic intervention.
108
 Animal studies suggest a mechanistic 
role of quinolonic acid, an NMDAR agonist, for inflammation-induced depression.
42
 Indeed 
RCTs of NMDAR antagonists, ketamine and compound AZD6765, have shown promising 
results for treatment resistant depression.
109-111
 Whilst safety and tolerability of ketamine may 
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limit its applicability in clinical setting, these findings provide further support for a role of 
inflammation in major mental illness. 
 
New therapeutics for immunologically stratified psychosis might be based on molecules and 
targets that are already well known in other therapeutic areas, allowing ‘repurposing’ of 
existing anti-inflammatory agents.
112
 Collaboration between industry and academia would be 
important to realise the potential of immune modulatory agents for the treatment of major 
mental illness. In the future studies should assess the prophylactic potential of immunological 
agents in individuals at high risk of developing psychosis. Longitudinal associations between 
higher levels of IL-6 and subsequent risks of psychosis,
2
 depression,
2
 heart disease,
113
 and 
type-two diabetes
114
 suggest that controlling inflammation might reduce the risk of a number 
of chronic adult diseases, and thus, have a huge beneficial effect at the population level. 
 
Conclusion 
Inflammation and immune dysfunction might contribute to cognitive, negative and positive 
symptoms in schizophrenia. We have highlighted several hypotheses and potential areas of 
interest for future research regarding the immunological aspects of schizophrenia. Addressing 
these issues would contribute to understanding disease mechanism and the development of 
effective new interventions, but requires integrated working between several disciplines. 
While animal model studies have much to offer in terms of understanding specific biological 
systems, these findings need to be confirmed in human subjects. This highlights the scope for 
translational research in schizophrenia over the coming years encompassing immune, genetic, 
microbiological, and other biomarkers. 
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Figure 1: How peripheral immune signals reach the brain to contribute to neuropsychiatric symptoms 
Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Neuroscience 2008; 9(1): 46-56, copyright 2008 
Sections A and B has been reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Neuroscience 2008; 9(1): 46-56, copyright 
2008 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Activation of innate immune 
response from infection, 
systemic inflammation, etc. 
Increase in circulating 
proinflammatory cytokines, such as 
IL-1β, TNF-α, IL-6 produced by 
macrophage and other cells 
In CNS, release of cytokines by 
activated microglia, periventricular 
macrophage and endothelial cells 
Neurochemical changes 
leading to altered mood, 
cognition and behaviour 
Neural and humoral 
pathways communicate 
the peripheral immune 
signal to the brain 
Figure 1 will appear here 
 
Please see attached hand drawn Figure 1, which will be created as an artwork with the help of an illustrator from 
the Journal. 
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Figure 2: Possible mechanisms of immune-mediated aetiology of psychosis  
 
 
                    
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 will appear here 
  
Please see attached slide 
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Table 1: Anti-inflammatory agents in the treatment of schizophrenia and related psychosis 
 
Study Design and setting Sample and source Outcome and exposure 
measurement 
Main findings Strengths and limitations 
Longitudinal study of treatment with Non-Steroidal Anti-inflammatory Drugs (NSAIDs) and schizophrenia risk 
Laan et al 
2007
115
 
Nested case control design; 
compares incidence of 
schizophrenia in users and 
non-users of prescribed 
NSAIDs  
82 schizophrenia and 359 controls 
from routine register 
Outcome: new prescription 
for antipsychotics for ≥3 
months as proxy for incident 
schizophrenia. 
Exposure: prescription for 
NSAIDs in the preceding 
four years. 
No association overall, but 
after adjusting for age and 
prescription frequency, 
protective effect of NSAID 
use in men, OR for 
schizophrenia 0.41 (95% 
CI 0.17- 0.97) 
Strengths: large population-
based study 
Limitations: no direct 
assessment for 
schizophrenia or NSAID 
use; short follow-up; 
included young individuals 
Stolk et al 
2007
116
 
Nested case control design; 
compares exacerbation of 
schizophrenia in users and 
non-users of prescribed 
NSAIDs 
Exacerbation of psychotic symptoms 
(case event; n=1443) compared with 
non-exacerbation (control event; 
n=1443) in ICD-9 schizophrenia 
cases receiving antipsychotic therapy 
+/- NSAIDs from routine register 
Case event: change of 
antipsychotic, increase in 
dose, use of combination or 
parenteral treatment 
Exposure: NSAIDs use 90 
days prior to case event 
No association overall; 
Cox-2 inhibitors led to 
exacerbation of symptoms, 
OR=2.56 (95% CI 1.35- 
4.87) 
Strengths: large population-
based study 
Limitation: no direct 
assessment for exacerbation 
of symptoms, prescription as 
proxy for NSAIDs use 
Randomised Controlled Trial (RCT) of NSAIDs as adjunct of antipsychotic treatment in schizophrenia 
Laan et al 
2010
117
 
Double blind RCT of 
antipsychotic plus Aspirin 
(1 gram daily) or placebo 
Trial duration: 90 days  
Analysis: Intention to treat 
(ITT) 
37 Aspirin vs. 33 placebo 
Inclusion criteria: DSM-IV 
schizophrenia, aged 18- 55 years, 
illness duration <10 years. Exclusion 
criteria: contraindication to or chronic 
use of NSAIDs, stomach illness, 
corticosteroid use, pregnancy 
Outcome measures: PANSS 
total, positive, negative, and 
general psychopathology 
sub-scores, cognitive tests, 
immunologic markers 
In the Aspirin group, 
statistically significant 
improvement in total and 
positive PANSS score 
(Cohen’s d 0.47 and 0.39, 
respectively) 
Strengths: double blind 
RCT, included both in and 
outpatient cases, and various 
clinical outcome measures 
Limitations: Small sample, 
short duration, high attrition 
 
Baheti et al 
2013
118
 
Open labelled trial of 
Celecoxib (400mgs daily). 
Trial duration: 42 days 
Analysis: study completers 
31 Celecoxib + Olanzapine vs. 31 
Olanzapine only 
Inclusion criteria: ICD-10 
schizophrenia with acute relapse 
Exclusion criteria: comorbid physical 
or other psychiatric illness, treatment-
resistant schizophrenia, PANSS score 
Outcome measures: PANSS 
total, positive, negative, and 
general psychopathology 
sub-scores 
Significantly lower 
positive, negative and 
general psychopathology 
scores at 3 and 6 weeks in 
the Celecoxib, compared 
with Olanzapine only 
group.  
Strength: objective outcome 
measure 
Limitations: small sample, 
short duration, no placebo or 
blinding of assessment 
37 
 
< 80 or > 120. 
Muller et al 
2002
101† 
Muller et al 
2004
119† 
Muller et al 
2005
102† 
Double blind RCT of 
Risperidone (2-6mgs 
daily) plus Celecoxib 
(400mgs daily) or placebo  
Trial duration: 35 days  
Analysis: ITT 
25 Celecoxib vs. 25 placebo 
Inclusion criteria: DSM-IV 
schizophrenia, aged 18- 65 years 
 
 
Outcome measures: PANSS 
scores; cognitive factor of 
the PANSS scale; serum 
immunologic measures  
Total PANSS score lower 
in the Celecoxib arm; no 
difference on cognitive 
measures;  lower baseline 
TNF-R1 predicted better 
response to Celecoxib 
Strengths: double blind 
RCT, use of plasma drug 
levels for monitoring 
Limitations: Small sample, 
and short duration 
Rapaport et al 
2005
120‡ 
Bresee et al 
2006
121‡ 
Double blind RCT of 
Risperidone/ Olanzapine 
plus Celecoxib (400mgs 
daily) or placebo 
Trial duration: 56 days 
18 Celecoxib vs. 17 placebo 
Inclusion criteria: stable outpatient 
cases of DSM-IV schizophrenia. 
Exclusion criteria: use of other 
antipsychotics, other criteria similar 
to Laan et al 2010. 
Outcome measures: PANSS, 
SANS, CGI, CDS, HAM-A 
scales; serum cytokine levels 
No difference between 
groups on any measures 
 
Strengths: RCT, used 
various outcome measures 
Limitations: only included 
stable cases, analysed trial 
completers, small sample, 
and short duration 
Akhondzadeh 
et al 2007
72
 
Double blind RCT of 
Risperidone (6mgs daily) 
plus Celecoxib (400mgs 
daily) or placebo  
Trial duration: 56 weeks 
Analysis: ITT 
30 Celecoxib vs. 30 placebo 
Inclusion criteria: inpatient DSM-IV 
schizophrenia, aged 19-44 years. 
Exclusion criteria: organic disease or 
substance dependence, other 
psychotic illness, peptic ulcer, GI 
bleeding, pregnancy or lactation 
Outcomes: PANSS scores Statistically significant 
improvement in PANSS 
total, positive, and general 
scores in the Celecoxib 
arm 
Strengths: double blind 
RCT, low drop out 
Limitations: small sample, 
short duration of trial 
Muller et al 
2010
73
 
Double blind RCT of 
Amisulpride plus 
Celecoxib (400mgs daily) 
or placebo 
Trial duration: 42 days 
25 Celecoxib vs. 25 placebo 
Inclusion criteria: inpatient cases of 
DSM-IV schizophrenia or 
schizophreniform disorder, aged 19- 
44 years, illness duration <2 years 
Outcomes: PANSS and CGI 
 
Statistically significant 
global clinical 
improvement in the 
Celecoxib arm using ITT 
analysis 
Strength: double blind RCT 
Limitations: small sample, 
short duration, and high 
attrition 
RCT of Minocycline as an adjunct of antipsychotic treatment in schizophrenia 
Levkovitz et 
al 2010
105
 
Double blind RCT of 
antipsychotic plus 
Minocycline (200mgs 
daily) or placebo  
Trial duration: 26 weeks 
36 Minocycline vs. 18 placebo 
Inclusion criteria: DSM-IV 
schizophrenia, aged 18- 35 years, 
illness duration <5 years. Exclusion 
criteria: contraindication to or use of 
Minocycline in last 6 months, 
compulsory hospitalization, others 
similar to Akhondzadeh et al 
Outcomes: SANS, PANSS, 
CGI, CDS, ITAQ, CANTAB 
 
In the minocycline arm, 
statistically significant 
improvement in negative 
symptoms, executive 
function, clinical status, 
and general functioning 
starting from week 14. 
Strength: double blind RCT, 
use of clinical, cognitive, 
and functional outcome 
measures, long duration 
Limitation: small sample, 
high attrition 
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Chaudhry et al 
2012
104
 
Double blind RCT of 
standard antipsychotic 
treatment plus 
Minocycline (200mgs 
daily) or placebo  
Trial duration: 52 weeks 
Analysis: ITT 
71 Minocycline vs. 73 placebo 
Inclusion criteria: DSM-IV in or 
outpatient cases of schizophrenia, and 
related psychosis, aged 18–65 years, 
diagnosis <5 years, stable on 
medication. Exclusion criteria: 
similar to Levkovitz et al 
Outcomes: PANSS, CGI, 
GAF, CANTAB 
In the Minocycline arm, 
statistically significant 
improvement in negative 
symptoms  
Strength: double blind RCT, 
use of clinical, cognitive, 
and functional outcome 
measures, long trial duration 
Limitation: small sample, 
high attrition 
Case reports of Minocycline and Aspirin as an adjunct of antipsychotic treatment in schizophrenia 
Webb et al 
2013
122
 
Aspirin (650mgs daily) 
plus Aripiprazole 20mgs 
daily 
A 13 year old Hispanic male with 
schizophrenia 
Outcome: PANSS score and 
clinical impression 
Hallucinations, speed and 
social communication 
improved in a few days.  
Strength: early-onset case 
Limitation: only one case, 
no control group   
Jhamnani et al 
2013
123
 
Minocycline (10mgs daily) 
plus atypical antipsychotic 
for 2-3 months  
Two cases of ICD-10 schizophrenia 
with persistent negative symptoms 
Outcome: SANS and SAPS Improvement in negative 
symptoms and serum CRP 
levels compared with 
baseline 
Strength: use of CRP and 
psychopathology measures 
Limitation: no control group  
Miyaoko et al 
2008
124
 
Minocycline (200-450mgs 
daily) plus atypical 
antipsychotic for 4 weeks 
22 in or outpatient cases of DSM-IV 
schizophrenia not responding to 
current treatment 
Outcome: PANSS Significant decrease in 
positive and negative 
symptoms after 4-8 weeks 
Strength: large case series 
Limitation: no control group  
Miyaoko et al 
2007
125
 
Minocycline (150mgs 
daily) plus Haloperidol/ 
Risperidone for 10-11 
weeks 
Two male DSM-IV schizophrenia 
cases with prominent catatonic 
features and concurrent infection 
Outcome: clinical 
impression 
Clinical improvement in 
both cases 
Limitation: only two cases, 
no control group 
Chaves et al 
2010
126
 
Minocycline (200mgs 
daily) plus Haloperidol for 
8 weeks 
One, 19 year old man with a five year 
history of  treatment resistant DSM-
IV schizophrenia 
Outcome: PANSS score, and 
brain scan 
 
Improvement in positive 
symptoms, and decrease in 
hyperperfusion of posterior 
cingulate gyrus 
Strength: use of 
neuroimaging data 
Limitation: only one case, 
no control group 
Kelly et al 
2011
127
 
Minocycline (200mgs 
daily) plus Clozapine for 
up to 16 weeks 
Two cases of schizophrenia with 
catatonic symptoms  
Outcome: BPRS, SANS, 
CDS 
In both cases, 
improvement in negative 
and positive symptoms 
Limitation:  only two cases, 
no control group 
Note: ‡, †= articles share the same sample but focus on different outcomes;  PANSS= Positive and negative syndrome scale; DSM-IV= Diagnostic and statistical manual of 
mental disorders fourth edition; TNF= Tumour necrosis factor alpha; SANS= Scale for the Assessment of Negative Symptoms; SAPS= Scale for assessment of positive 
symptoms ;CGI= Clinical Global Impressions Scale; HAM-A= Hamilton Anxiety Rating Scale; CDS= Calgary depression scale for schizophrenia; ITAQ= Insight and 
treatment attitude questionnaire; CANTAB= Cambridge neuropsychological test automated battery; GAF= Global Assessment of Functioning; BPRS= Brief Psychiatric 
Rating Scale 
